BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22994749)

  • 21. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Kim K; Wu HG; Kim HJ; Sung MW; Kim KH; Lee SH; Heo DS; Kim HJ; Park CI
    Head Neck; 2009 Sep; 31(9):1121-8. PubMed ID: 19340863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB-IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): a mono-institutional experience.
    Franchin G; Vaccher E; Talamini R; Politi D; Gobitti C; Minatel E; Lleshi A; Sartor G; Mascarin M; Rumeileh IA; Trovò MG; Barzan L
    Oral Oncol; 2011 Sep; 47(9):905-9. PubMed ID: 21783403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advantages of intensity modulated radiotherapy in recurrent T1-2 nasopharyngeal carcinoma: a retrospective study.
    Qiu S; Lu J; Zheng W; Xu L; Lin S; Huang C; Xu Y; Huang L; Pan J
    BMC Cancer; 2014 Nov; 14():797. PubMed ID: 25366703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta-analysis and a systematic review of the literature.
    Co J; Mejia MB; Dizon JM
    Head Neck; 2016 Apr; 38 Suppl 1():E2130-42. PubMed ID: 25546181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of late toxicity in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy.
    Zheng Y; Han F; Xiao W; Xiang Y; Lu L; Deng X; Cui N; Zhao C
    Radiat Oncol; 2015 Jan; 10():17. PubMed ID: 25582731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma.
    Lee SW; Back GM; Yi BY; Choi EK; Ahn SD; Shin SS; Kim JH; Kim SY; Lee BJ; Nam SY; Choi SH; Kim SB; Park JH; Lee KK; Park SH; Kim JH
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):152-60. PubMed ID: 16472934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma.
    Lee VH; Kwong DL; Leung TW; Ng SC; Lam KO; Tong CC; Sze CK
    Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):1067-1078. PubMed ID: 27738820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II nasopharyngeal carcinoma.
    Pan XB; Huang ST; Chen KH; Jiang YM; Ma JL; Qu S; Li L; Chen L; Zhu XD
    Oncotarget; 2017 Jul; 8(28):46211-46218. PubMed ID: 28515352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of results of treatment for nasopharyngeal carcinoma in Penang General Hospital from 2001-2005.
    Phua CE; Tan BS; Yong TK; Govindasamy M
    Asian Pac J Cancer Prev; 2011; 12(12):3197-200. PubMed ID: 22471453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma.
    Liu F; Xi XP; Wang H; Han YQ; Xiao F; Hu Y; He Q; Zhang L; Xiao Q; Liu L; Luo L; Li Y; Mo Y; Ma HZ
    Radiat Oncol; 2017 Jan; 12(1):15. PubMed ID: 28587681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
    You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
    Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcome for nasopharyngeal carcinoma in University Malaya Medical Centre from 2004-2008.
    Chee Ee Phua V; Loo WH; Yusof MM; Wan Ishak WZ; Tho LM; Ung NM
    Asian Pac J Cancer Prev; 2013; 14(8):4567-70. PubMed ID: 24083703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy.
    Huang TL; Chien CY; Tsai WL; Liao KC; Chou SY; Lin HC; Dean Luo S; Lee TF; Lee CH; Fang FM
    Head Neck; 2016 Apr; 38 Suppl 1():E1026-32. PubMed ID: 26041548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.
    Wu F; Wang R; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K
    Radiother Oncol; 2014 Jul; 112(1):106-11. PubMed ID: 24933452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
    Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma.
    Qiu S; Lin S; Tham IW; Pan J; Lu J; Lu JJ
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):676-83. PubMed ID: 22024207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IMRT-SIB with concurrent and neo-adjuvant platinum-based chemotherapy for locally advanced head and neck squamous cell cancer: analysis of clinical outcomes in a retrospective series of a single institution.
    Mazzeo E; Antognoni P; Parmiggiani M; D'Ambrosio C; De Marco G; Marra L; Gottardi G; Bertoni F
    Tumori; 2014; 100(6):652-9. PubMed ID: 25688499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.